Aspirin and Dementia: Who Was Found to Have a Lower Risk

Published on: ⋄5 min read
Author: Valeriia Voronova, Editor at SOD Energy
Genetic characteristics as a possible factor in differences in aspirin’s effect on dementia risk

Could ordinary aspirin help protect the brain from dementia? For a long time, studies have offered no convincing reason to consider it an effective means of prevention. However, researchers at Monash University found an unexpected pattern: in people with certain genetic characteristics, low-dose aspirin may be associated with a significantly lower risk of developing dementia.

A reanalysis of data from a large clinical trial showed that participants with a high genetically predicted platelet count had an approximately 70% lower relative risk of dementia while taking aspirin than those in the placebo group.

The findings of the study, published on September 24, 2026, in the journal Alzheimer's & Dementia, open up a new direction for research into personalized dementia prevention. However, the conclusions are based on an exploratory analysis of previously collected data and require independent confirmation. For now, taking aspirin to prevent dementia is not recommended: potential risks, including bleeding, may outweigh the benefits.

Which genetic group did the researchers identify?

The team, led by Peter Franks, analyzed genetic data from 13,541 participants in the ASPREE study. Their average age was 75, and the median follow-up period was 4.6 years. In the original double-blind randomized trial, participants were randomly assigned to take 100 mg of aspirin daily or a placebo.

The researchers wanted to find out whether heredity could explain differences in response to the medication. To do this, they tested 1,848 polygenic scores. Each score combines the contributions of many genetic variants associated with a particular trait.

The most notable result was found among participants in the top 20% for one of the scores associated with platelet count. This is not a separate “dementia gene”, but an overall genetic characteristic. It also does not mean that a person necessarily has an elevated platelet count in their blood.

How many genetic variants are combined into a platelet-related score
A polygenic score sums the contributions of many genetic variants. It cannot be replaced by testing a single gene.

What does a 70% reduction in dementia risk mean?

The relative estimate of about 70% takes the time to dementia onset into account. To understand the scale of the difference, it is also helpful to look at the proportions of participants who experienced these events. The Monash University news release reports the following results for the identified genetic subgroup:

Event during the follow-up period

Aspirin

Placebo

Development of dementia

1%

3.3%

Serious bleeding

4.4%

2.1%

The absolute difference in dementia rates was about 2.3 percentage points. In other words, this does not mean that aspirin prevented dementia in 70 out of every 100 people.

At the same time, serious bleeding was more common. The absolute difference here was also about 2.3 percentage points, but this numerical match does not mean the benefits and harms are equivalent: dementia and bleeding differ in their consequences, severity, and timing. A single measure of risk reduction is not enough to decide whether to prescribe a medication.

How might platelets be linked to aspirin’s effects?

Platelets help stop bleeding: they attach to a damaged area of a blood vessel and form a clump. Low-dose aspirin irreversibly suppresses the enzyme cyclooxygenase-1 in platelets. As a result, the production of thromboxane–a substance that promotes platelet clumping–decreases. This same action explains the increased risk of bleeding.

The genetic finding’s connection to platelets is therefore biologically plausible. The condition of blood vessels and impaired blood flow can affect brain function; changes in platelet activity could potentially influence this pathway.

However, this explanation remains a hypothesis in relation to the new finding. The analysis did not measure actual platelet counts or function, so it does not show exactly what mechanism might account for the difference in dementia rates. The genetic association helps point to a direction for further research, but it does not, by itself, reveal the whole chain of cause and effect.

Why does this result differ from earlier findings on aspirin?

The main analysis of cognitive outcomes in ASPREE, published in the journal Neurology in 2020, included more than 19,000 people. Aspirin showed no preventive effect against dementia, mild cognitive impairment, or cognitive decline in the overall group.

The new study asks a narrower question: might responses to the medication differ depending on inherited characteristics? The overall trial result and the effect within a particular subgroup could, in theory, differ. That is why the genetic analysis is of interest for personalized prevention.

The main limitation is that this prevention strategy was not tested in a trial designed in advance for that purpose. The subgroup was identified after the data had been collected, by testing many scores. Three platelet-related scores passed a strict statistical correction for multiple comparisons, but selecting the strongest signal may still exaggerate the size of the effect.

In addition, about 97% of participants were of European ancestry. The applicability of this genetic criterion to people of other ancestries remains to be established. The effects of learning new languages on dementia were explored in this article.

What does this finding change for dementia prevention?

For the general public, the finding does not change current recommendations: you should not start taking aspirin on your own to preserve your memory. If you have already been prescribed the medication for another reason, this study is also not a reason to stop taking it or change the dose without consulting your doctor.

The scientific value of the finding lies elsewhere: it offers a specific genetic criterion to test. The next step is to reproduce the result using independent data and conduct a separate trial that selects participants according to this criterion in advance. The trial would need to assess both dementia and serious bleeding. Only this approach can show whether genetic screening can identify people for whom the balance of benefits and risks is genuinely favorable.

Can a routine blood test identify the relevant group?

No. A routine blood test does not reproduce the polygenic score used in the study. It measures a person’s current platelet count, whereas the researchers assessed a combination of inherited variants. A high platelet count by itself does not mean that aspirin will help someone prevent dementia.

Can an APOE test show whether I should take aspirin?

This study does not provide grounds for using APOE to make that decision. The authors found no statistically significant difference in aspirin’s effect depending on APOE genotype. They also found no similar interaction with polygenic risk scores for dementia and Alzheimer’s disease.

Can this result be considered evidence that aspirin prevents Alzheimer’s disease?

No. The researchers assessed dementia from all causes and did not analyze its subtypes separately. Therefore, the association they found cannot be attributed specifically to the prevention of Alzheimer’s disease.

How was this article?

 

Share

Explore more